10-[(1-甲基哌啶-4-基)甲基]吩噻嗪 | 3772-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 10-[(1-甲基哌啶-4-基)甲基]吩噻嗪
• 英文名称: 10-((1-Methyl-4-piperidyl)methyl)phenothiazine
• 英文别名: 10-[(1-methylpiperidin-4-yl)methyl]phenothiazine
• CAS: 3772-71-2
• 化学式: C₁₉H₂₂N₂S
• 分子量: 310.5
• InChiKey: DLAKWHKNGHJWKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  31.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934300000

文献信息

• PHENOTHIAZINE DERIVATIVES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
  申请人：Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH

  公开号：EP3473254A1

  公开（公告）日：2019-04-24

  The invention relates to a compound for use in treating a cancer, wherein the cancer depends on the proteolytic activity of the MALT1 protease, and wherein the compound has the general formula (I) wherein X is N or C; Y is S, O, SO2, SO, NH, CO, CH2, CH=CH, or CH2-CH2; ()z is a C1-C5 linear or branched alkyl chain; A is NR3R4, or OR5, or HET; R1 and R2 in each occurrence are independently selected from -H, -CH3, -OH, -OCH3, -SCH3, -F, -CI, -CF3, -NH2, and-COOH; R3, R4, and R5 are H, or C1-C5 linear or branched alkyl groups, and HET is a heterocyclic ring of 5, 6, or 7 members, wherein the ring atoms can be C, O, N, or S, the ring can be saturated or aromatic, and the ring can be substituted with H or C1-C5 linear or branched alkyl groups; or a pharmaceutically acceptable salt, prodrug, enantiomer, diastereomer, racemic mixture, crystalline form, amorphous form, unsolvated form or solvate of said compound. The compound of the invention may further be used in the treatment of MALT1-dependent immune diseases

  本发明涉及一种用于治疗癌症的化合物，其中癌症依赖于 MALT1 蛋白酶的蛋白分解活性，且该化合物具有通式 (I) 其中 X 是 N 或 C；Y 是 S、O、SO2、SO、NH、CO、CH2、CH=CH 或 - ；()z 是 C1-C5 直链或支链烷基链；A 是 NR3R4、或 OR5、或 HET；每次出现的 R1 和 R2 独立选自-H、-CH3、-OH、-O 、-S 、-F、-CI、-CF3、-NH2 和-COOH；R3、R4 和 R5 是 H 或 C1-C5 直链或支链烷基，HET 是由 5、6 或 7 个成员组成的杂环，其中环原子可以是 C、O、N 或 S，环可以是饱和或芳香的，环可以被 H 或 C1-C5 直链或支链烷基取代；或所述化合物的药学上可接受的盐、原药、对映体、非对映体、外消旋混合物、结晶形式、无定形形式、未溶形式或溶解物。本发明的化合物可进一步用于治疗 MALT1 依赖性免疫疾病
• SELECTIVE INHIBITION OF MALT1 PROTEASE BY PHENOTHIAZINE DERIVATIVES
  申请人：Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)

  公开号：EP2739285A1

  公开（公告）日：2014-06-11
• Selective inhibition of MALT1 protease by phenothiazine derivatives
  申请人：Krappmann Daniel

  公开号：US20140288060A1

  公开（公告）日：2014-09-25

  The invention relates to a compound for use in treating a cancer, wherein the cancer depends on the proteolytic activity of the MALT1 protease, and wherein the compound has the general formula (I) wherein X is N or C; Y is S, O, SO 2 , SO, NH, CO, CH 2 , CH═CH, CH 2 ═CH 2 ; ( ) z is a C 1 -C 5 linear or branched alkyl chain; A is NR 3 R 4 , or OR 5 , or HET; R 1 and R 2 in each occurrence are independently selected from —H, —CH 3 , —OH, —OCH 3 , —SCH 3 , —F, —Cl, —CF 3 , —NH 2 , and —COOH; R 3 , R 4 , and R 5 are H, or C 1 -C 5 linear or branched alkyl groups, and HET is a heterocyclic ring of 5, 6, or 7 members, wherein the ring atoms can be C, O, N, or S, the ring can be saturated or aromatic, and the ring can be substituted with H or C 1 -C 5 linear or branched alkyl groups; or a pharmaceutically acceptable salt, prodrug, enantiomer, diastereomer, racemic mixture, crystalline form, amorphous form, unsolvated form or solvate of said compound. The compound of the invention may further be used in the treatment of MALT1-dependent immune diseases.
• US9504692B2
  申请人：——

  公开号：US9504692B2

  公开（公告）日：2016-11-29
• [EN] SELECTIVE INHIBITION OF MALT1 PROTEASE BY PHENOTHIAZINE DERIVATIVES<br/>[FR] INHIBITION SÉLECTIVE DE LA PROTÉASE MALT1 PAR DES DÉRIVÉS DE PHÉNOTHIAZINE
  申请人：HELMHOLTZ ZENTRUM MUENCHEN

  公开号：WO2013017637A1

  公开（公告）日：2013-02-07

  The invention relates to a compound for use in treating a cancer, wherein the cancer depends on the proteolytic activity of the MALT1 protease, and wherein the compound has the general formula (I) (I) wherein X is N or C; Y is S, O, SO2, SO, NH, CO, CH2, CH=CH, or CH2-CH2; ()z is a C1-C5 linear or branched alkyl chain; A is NR3R4, or OR5, or HET; R1 and R2 in each occurrence are independently selected from -H, -CH3, -OH, -OCH3, -SCH3, -F, -CI, -CF3, -NH2, and -COOH; R3, R4, and R5 are H, or C1-C5 linear or branched alkyl groups, and HET is a heterocyclic ring of 5, 6, or 7 members, wherein the ring atoms can be C, O, N, or S, the ring can be saturated or aromatic, and the ring can be substituted with H or C1-C5 linear or branched alkyl groups; or a pharmaceutically acceptable salt, prodrug, enantiomer, diastereomer, racemic mixture, crystalline form, amorphous form, unsolvated form or solvate of said compound. The compound of the invention may further be used in the treatment of MALT1 -dependent immune diseases.